PD-L1 antibody | ONCOdianova anti-human PD-L1 antibody for IHC

Clone JAL1 validated for IHC detection of PD-L1 in routine-fixed FFPE sections

PD-L1

Fig.02 PD-L1 staining of thyroid adenoma

Fig.03 PD-L1 positivity of thyroid adenoma

Fig.04 PD-L1 positivity of follicular thyroid carcinoma.

Fig.05 PD-L1 positive macrophages in a follicular thyroid carcinoma

Fig.06 Strong PD-L1 positivity in anaplastic thyroid carcinoma

Fig.07 Intense PD-L1 stain in anaplastic thyroid carcinoma

Fig.08 PD-L1 in an anaplastic thyroid carcinoma

Fig.09 PD-L1 in macrophages of a cervical uterine adenocarcinoma.

Fig.10 PD-L1 expression in squamous cell carcinoma of the cervix uteri

Fig.11 PD-L1 in a squamous cell carcinoma of the cervix

Fig.12 PD-L1 expression in a medullary breast carcinoma

Fig.13 PD-L1 in a chromophobic renal cell carcinoma

Fig.14 PD-L1 positivity in a chromophobic renal cell carcinoma

Fig.15 PD-L1 in a papillary renal cell carcinoma

Fig.16 Strong PD-L1 positivity in a papillary renal cell carcinoma

Fig.17 Focal PD-L1 positivity in a kidney oncocytoma

Fig.18 Strong focal PD-L1 positivity in a kidney oncocytoma

Fig.19 Strong PD-L1 positivity in a kidney oncocytoma

Fig.20 PD-L1 positive inflammatory cells of a seminoma

Fig.21 PD-L1 positive inflammatory cells of a seminoma

Fig.22 PD-L1 expression in a pheochromocytoma

Fig.23 PD-L1 in a gastrointestinal stromal tumor

Fig.24 PD-L1 in squamous cell carcinoma of the skin

Fig.25 PD-L1 positivity in a thymoma

Fig.26 Thymoma with PD-L1 expression in epithelial cells

Fig.27 Strong expression of PD-L1 in a small cell bronchial carcinoma

Fig.28 PD-L1 in Merkel cell carcinoma the skin

Fig.29 Bladder cancer with strong PD-L1 signal

Fig.30 PD-L1 positivity IHC in a dedifferentiated liposarcoma

Fig.31 Liposarcoma with strong PD-L1 expression

Fig.32 Malignant mesothelioma with strong PD-L1 expression

Fig.33 Leiomyosarcoma with PD-L1 expression

Fig.34 PD-L1 in squamous cell carcinoma of the mouth

Fig.35 PD-L1 expression in a Non-Hodgkin's lymphoma

Fig.36 PD-L1 expression in a Non-Hodgkin's lymphoma

Fig.37 Non-Hodgkin's lymphoma with intensive PD-L1 signal

Fig.38 Intensive PD-L1 staining in a Hodgkin lymphoma

Fig.39 PD-L1 positive Hodgkin's lymphoma

PD-L1, also known as CD274 or B7 homolog 1 (B7-H1) is highly expressed in the heart, skeletal muscle, placenta and lung and weakly expressed in the thymus, spleen, kidney and liver. PD-L1 is expressed on macrophages and activated T- and B-cells, dendritic cells, keratinocytes and monocytes. Moreover, several human cancer cells express PD-L1 at high levels. Binding of PD-L1 with its receptor PD-1 on T cells inhibits t cell proliferation and the production of cytokines, such as interleukin (IL)-2. It has been shown that PD-L1 helps tumor cells to evade anti-tumor immunity and blockade of PD-L1 reduces the growth of tumors in the presence of immune cells.

PD-L1 is commonly over expressed on tumor cells or on non-transformed cells in the tumor microenvironment. PD-L1 ex-pressed on the tumor cells binds to PD-1 receptors on the activated T cells, which leads to the inhibition of the cytotoxic T cells. These deactivated T cells remain inhibited in the tumor microenvironment. PD-1 and PD-L1/PD-L2 belong to the family of immune checkpoint proteins that act as co-inhibitory factors, which can halt or limit the development of the T cell response.

Anti-PD-L1 antibody Clone JAL1 has been developed specifically for routine immunohistochemical (IHC) detection of PD-L1 in formalin-fixed paraffin-embedded tissue specimen. Moreover, JAL1 has been validated for the identification of PD-L1-positive macrophages and tumor tissues under pathological conditions.

PD-L1 Antibody Productdetails

EXPLORE